Secondary Logo

Most Popular Articles

Characterization of ADME gene variation in 21 populations by exome sequencing

Hovelson, Daniel H.; Xue, Zhengyu; Zawistowski, Matthew; More

Pharmacogenetics and Genomics. 27(3):89-100, March 2017.

Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia

Griese, Ernst-Ulrich; Ilett, Kenneth F.; Kitteringham, Neil R.; More

Pharmacogenetics. 11(1):69-76, February 2001.

CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case–control study

Figueiras, Adolfo; Estany-Gestal, Ana; Aguirre, Carmelo; More

Pharmacogenetics and Genomics. 26(2):66-73, February 2016.

Cancer patients’ acceptance, understanding, and willingness-to-pay for pharmacogenomic testing

Cuffe, Sinead; Hon, Henrique; Qiu, Xin; More

Pharmacogenetics and Genomics. 24(7):348-355, July 2014.

Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202

Verma, Anurag; Bradford, Yuki; Verma, Shefali S.; More

Pharmacogenetics and Genomics. 27(3):101-111, March 2017.

Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial

Ruiz-Pinto, Sara; Martin, Miguel; Pita, Guillermo; More

Pharmacogenetics and Genomics. 28(11):245-250, November 2018.

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

Niemi, Mikko; Schaeffeler, Elke; Lang, Thomas; More

Pharmacogenetics. 14(7):429-440, July 2004.

TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity

Thiesen, Signe; Yin, Peng; Jorgensen, Andrea L.; More

Pharmacogenetics and Genomics. 27(6):213-222, June 2017.

The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting

Harmsze, Ankie M.; van Werkum, Jochem W.; Hackeng, Christian M.; More

Pharmacogenetics and Genomics. 22(3):169-175, March 2012.

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism

Schwab, Matthias; Schäffeler, Elke; Marx, Claudia; More

Pharmacogenetics. 12(6):429-436, August 2002.

Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure

de Groote, Pascal; Helbecque, Nicole; Lamblin, Nicolas; More

Pharmacogenetics and Genomics. 15(3):137-142, March 2005.

Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics

Niemi, Mikko; Arnold, Katja A.; Backman, Janne T.; More

Pharmacogenetics and Genomics. 16(11):801-808, November 2006.

Identification and functional characterization of eight CYP3A4 protein variants

Eiselt, Regina; Domanski, Tammy L.; Zibat, Arne; More

Pharmacogenetics. 11(5):447-458, July 2001.

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

Schmid, Yasmin; Vizeli, Patrick; Hysek, Cédric M.; More

Pharmacogenetics and Genomics. 26(8):397-401, August 2016.

Expression of ABC-type transport proteins in human platelets

Nieen, Juliane; Jedlitschky, Gabriele; Grube, Markus; More

Pharmacogenetics and Genomics. 20(6):396-400, June 2010.

Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs

Delacrétaz, Aurélie; Lagares Santos, Patricia; Saigi Morgui, Nuria; More

Pharmacogenetics and Genomics. 27(12):464-472, December 2017.

Pharmacogenomic characterization of gemcitabine response – a framework for data integration to enable personalized medicine

Harris, Michael; Bhuvaneshwar, Krithika; Natarajan, Thanemozhi; More

Pharmacogenetics and Genomics. 24(2):81-93, February 2014.

Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide

Singh, Sonal; Wang, Zhiying; Shahin, Mohamed H.; More

Pharmacogenetics and Genomics. 28(11):251-255, November 2018.

The genetic determinants of the CYP3A5 polymorphism

Hustert, Elisabeth; Haberl, Michael; Burk, Oliver; More

Pharmacogenetics. 11(9):773-779, December 2001.

A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma

Pillai, Sreekumar G; Cousens, Diane J; Barnes, Ashley A; More

Pharmacogenetics. 14(9):627-633, September 2004.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28

Minami, Hironobu; Sai, Kimie; Saeki, Mayumi; More

Pharmacogenetics and Genomics. 17(7):497-504, July 2007.

No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARδ and PPARγ act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma

McGreavey, Louise E.; Turner, Faye; Smith, Gillian; More

Pharmacogenetics and Genomics. 15(10):713-721, October 2005.

Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1)

Fujita, Tomoe; Brown, Chaline; Carlson, Elaine J.; More

Pharmacogenetics and Genomics. 15(4):201-209, April 2005.

Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype

Selinski, Silvia; Blaszkewicz, Meinolf; Lehmann, Marie-Louise; More

Pharmacogenetics and Genomics. 21(10):673-678, October 2011.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

Takahashi, Harumi; Wilkinson, Grant R.; Nutescu, Edith A.; More

Pharmacogenetics and Genomics. 16(2):101-110, February 2006.

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis

Zuo, Xiao-cong; Ng, Chee M.; Barrett, Jeffrey S.; More

Pharmacogenetics and Genomics. 23(5):251-261, May 2013.

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

Haufroid, Vincent; Mourad, Michel; Van Kerckhove, Valérie; More

Pharmacogenetics. 14(3):147-154, March 2004.

Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation

Mercier, Cédric; Raynal, Caroline; Dahan, Laetitia; More

Pharmacogenetics and Genomics. 17(10):841-844, October 2007.

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients

Etienne, Marie-Christine; Formento, Jean-Louis; Chazal, Maurice; More

Pharmacogenetics. 14(12):785-792, December 2004.